Perioperative Tranexamic Acid in Pelvic Fixation Is Associated with Reduced Postoperative Transfusions: A Retrospective Cohort Study
This retrospective cohort study utilizing propensity score matching found that perioperative tranexamic acid administration in patients undergoing pelvic fixation significantly reduced postoperative transfusion rates and ICU admissions without increasing the risk of thromboembolic events or other adverse complications.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person suffers a severe break in the pelvis or hip socket, the injury often brings a dangerous side effect: heavy bleeding. The pelvis is a large, complex ring of bone surrounded by major blood vessels, and when it shatters, the body can lose a significant amount of blood very quickly. To survive and heal, these patients often need surgery to hold the broken pieces together. During and after such operations, doctors sometimes have to give patients blood from donors to replace what was lost. While this life-saving treatment is common, it carries its own risks, including a higher chance of infection or blood clots. For years, surgeons have used a specific medication called tranexamic acid to help stop bleeding in other types of bone surgeries, like fixing broken thigh bones. This drug works by helping the body's natural clotting system hold on to blood clots longer, preventing them from dissolving too soon. However, while its benefits in hip surgery are well known, it remained unclear whether using this same drug for the more complex and dangerous pelvic fractures would help reduce the need for blood transfusions without causing new problems.
A team of researchers set out to answer this question by looking at a massive collection of real-world medical records. They focused on adults who had undergone surgery to fix fractures in their pelvic ring or hip socket. The study compared two groups of patients: those who received the bleeding-control medication around the time of their operation and those who did not. To ensure a fair comparison, the researchers used a sophisticated matching process to pair patients who were nearly identical in age, gender, health history, and the severity of their injuries. This method helped isolate the effect of the medication itself, removing the influence of other factors that might make one group of patients sicker or more likely to need blood than the other. The final analysis included nearly eight thousand patients, split evenly between those who got the drug and those who did not, all tracked for up to ninety days after their surgery.
The results showed a clear and consistent benefit for the patients who received the medication. In the group that did not get the drug, about 5.7 percent of patients required a blood transfusion within three days of surgery. In the group that did receive the drug, that number dropped to 4.1 percent. This difference held true as time went on; at ninety days after the operation, 7.3 percent of the untreated group needed blood, compared to only 5.2 percent of the treated group. The data suggests that using the medication lowered the risk of needing a transfusion by roughly thirty percent across all time periods measured. This reduction means that for every hundred patients treated, about two fewer would require a blood transfusion, a small but meaningful improvement that could lower the overall risk of complications for the entire group.
Beyond just reducing the need for blood, the researchers also checked to see if the medication caused any hidden dangers. There was a long-standing concern that helping the blood clot more effectively might increase the risk of dangerous clots forming in the veins or lungs, or lead to other serious issues like kidney failure or infection. The study found no evidence of this. The rates of blood clots, kidney problems, severe infections, and death were essentially the same in both groups. This indicates that the medication can be used to spare blood without trading one risk for another. The treated group also showed lower rates of admission to the intensive care unit, though the researchers noted that these numbers were very low overall and should be viewed with some caution.
This large-scale review of patient data suggests that adding this specific medication to the standard care for pelvic fracture surgery is a safe and effective way to reduce the need for blood transfusions. While the study was based on past records rather than a new experiment, the consistency of the results across thousands of patients provides strong support for the idea. It offers surgeons a tool that may help patients recover with fewer complications related to blood loss, without introducing new threats to their safety. The findings add a piece of clarity to a field where the best practices for these difficult injuries have not always been certain, pointing toward a simpler, safer path for patients facing some of the most severe orthopedic trauma.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.